Microneedles Based Thermally Stable Ad‐5 Viral Vector for Vaccine Delivery
Makaleler > Tam Makale · 2026
Yazarlar: Parbeen Singh, Nidhi Sharma, Feifei Huang, Nitu Bhaskar, Hasan AKBABA, Jinyoung Park, Akshar Radhakrishnan, Aseno Sakhrie, Lam Nguyen, Gang Ge, Cao‐Sang Truong, Achal Duhoon, Maria Palmtag, I'jaaz Muhammad, Monica Rodriguez‐Calzada, Neha Mishra, Steven M. Szczepanek, Gisselle N. Medina, Thanh Duc Nguyen
Advanced Healthcare Materials, Uluslararası, Wos, 2026, cilt 15, ss e04342-e04342
Özet
Cold chain dependence and inconvenient needle/syringe-based injections limit the global deployment of adenoviral (Ad) vectored vaccines, which play significant roles in veterinary vaccinology and offer an effective tool to protect humans against potential pandemics/endemics. Herein, a new Ad5-FMD vaccine stabilizing and delivery technology is presented, termed as Stabilized Prophylactic Adenovirus Nanostructure Delivery via Microneedles (SPAND-MN), which enables room-temperature storage and easy-to-use, painless transdermal administration of Ad vectored vaccines. It is demonstrated the success of SPAND-MN platform to deliver replication-defective Adenovirus serotype 5 (Ad5) vaccine vectors expressing various antigens, including Green Fluorescent Protein (GFP), Luciferase (Luc), and Foot-and-Mouth Disease (FMD) capsid proteins. The SPAND-MN formulation preserved transduction capacity of the Ad5 vaccines after exposure to an accelerated temperature (at 60°C) and a long-term storage at 45°C for 1 month. In vitro and in vivo studies confirmed effective transduction efficiency, dose delivery, and biocompatibility of the SPAND-MN platform. In vivo safety assessments revealed no cytotoxicity, systemic inflammation, and organ toxicity. SPAND-MNs maintained immunogenicity equivalent to injections of the stock refrigerated vaccines even after thermal challenges. These results demonstrate the potential of SPAND-MNs to offer a powerful, easy-to-use, cold-chain free, and painless transdermal skin patch for Ad5 vaccination.